Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and Luigi Naldini, has unveiled a powerful strategy to rejuvenate the effectiveness of chimeric antigen receptor (CAR) T cell therapy against glioblastoma, one of the most lethal and treatment-resistant brain tumors.
A new study reveals the biological secret to the Zika virus's infectious success: Zika uses host cells' own "self-care" system of clearing away useless molecules to suppress the host proteins that the virus has employed to get into those cells in the first place.
Scientists and medics have developed an ultra-rapid method of genetically diagnosing brain tumors that will cut the time it takes to classify them from 6-8 weeks, to as little as two hours – which could improve care for thousands of patients each year in the UK.
Imagine a super-charged immune cell that can launch a focused attack on stubborn solid tumors - a smart fighter that destroys cancer cells for days without tiring.
A new review article highlights the transformative role of circular RNA (circRNA) in cancer, revealing its potential as both a key player in tumor biology and a promising avenue for future therapies.
A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research led by investigators at the Johns Hopkins Kimmel Cancer Center Bloomberg~Kimmel Institute for Cancer Immunotherapy and the Johns Hopkins University School of Medicine.
Cancer is rarely discussed in the same breath as liposuction or plastic surgery.
In a recent study, researchers from Uppsala University show that the Semliki Forest virus enters the central nervous system by first entering the cerebrospinal fluid and then binding to a specific cell type before penetrating deeper into the brain.
A cunning culprit that aids cancer cells in avoiding CAR T cell therapy has been identified by researchers at City of Hope®, one of the biggest and most cutting-edge cancer research and treatment organizations in the United States, with a comprehensive cancer center in Los Angeles that is ranked among the top five cancer centers in the country by US News & World Report.
Scientists are literally shining a laser on the energy centers of cancer cells in an attempt to harm these sources of power and cause widespread cancer cell death.
Researchers have found a way to program immune cells to attack glioblastoma and treat the inflammation of multiple sclerosis in mice.
Research from the Federal University of Rio de Janeiro (UFRJ) and the National Institute of Science and Technology for Structural Biology and Bioimaging (INBEB) in Brazil has uncovered a critical mechanism by which mutations in the p53 protein-;a key tumor suppressor known as the "guardian of the genome"-;turn other proteins into cancer-promoting agents
Glioblastomas are highly aggressive, usually incurable brain tumors. If all therapeutic options are exhausted, patients have an average life expectancy of less than two years.
The existing knowledge on monolayers and spheroid-based cell cultures, including the constituent compounds, and the difference in efficacy during drug screening, especially for anti-cancer drugs targeting cytoskeletal dynamics and cell cycles.
By super cooling a molecule on the surface of brain cells down to about minus 180 degrees Celsius -; nearly twice as cold as the coldest places in Antarctica -; scientists at Johns Hopkins Medicine say they have determined how a widely-used epilepsy drug works to dampen the excitability of brain cells and help to control, although not cure, seizures.
The Wistar Institute assistant professor Filippo Veglia, Ph.D., and team, have discovered a key mechanism of how glioblastoma -; a serious and often fatal brain cancer -; suppresses the immune system so that the tumor can grow unimpeded by the body's defenses.
Cancer cells release a significantly more concentrated level of acid than previously known, forming an "acid wall" that could deter immune cells from attacking tumors, UT Southwestern Medical Center scientists show in a new study.
Targeting two brain tumor-associated proteins-;rather than one-;with CAR T cell therapy shows promise as a strategy for reducing solid tumor growth in patients with recurrent glioblastoma (GBM), an aggressive form of brain cancer, according to early results from the first six patients treated in an ongoing Phase I clinical trial led by researchers from the Perelman School of Medicine at the University of Pennsylvania and Penn Medicine's Abramson Cancer Center.
While physicists continue to argue about whether time is indeed an illusion, as Albert Einstein claimed, biologists have no doubt about its significance for understanding life as a dynamic system.
A study conducted by pre-PhD researcher Pablo S. Valera and recently published in PNAS demonstrates the potential of surface-enhanced Raman spectroscopy (SERS) to explore metabolites secreted by cancer cells in cancer research.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.